1 – 21 of 21
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Burden of disease and management of osteoarthritis and chronic low back pain : Healthcare utilization and sick leave in Sweden, Norway, Finland and Denmark (BISCUITS): Study design and patient characteristics of a real world data study
(
- Contribution to journal › Article
- 2019
-
Mark
Clinical use of cangrelor : nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
(
- Contribution to journal › Article
- 2018
-
Mark
Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents
(
- Contribution to journal › Article
-
Mark
Caffeine and incidence of dyspnea in patients treated with ticagrelor
(
- Contribution to journal › Letter
-
Mark
Culprit and nonculprit recurrent ischemic events in patients with myocardial infarction : Data from SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies)
(
- Contribution to journal › Article
-
Mark
External Validation of the DAPT Score in a Nationwide Population
(
- Contribution to journal › Article
- 2017
-
Mark
Unfractionated heparin versus bivalirudin in patients undergoing primary percutaneous coronary intervention : A SWEDEHEART study
(
- Contribution to journal › Article
-
Mark
Outcome of percutaneous coronary intervention with the Absorb bioresorbable scaffold : Data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
(
- Contribution to journal › Article
-
Mark
Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
(
- Contribution to journal › Article
- 2016
-
Mark
Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment : A nationwide Swedish registry report
(
- Contribution to journal › Article
-
Mark
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction : Experiences from SWEDEHEART registry
(
- Contribution to journal › Article
- 2015
-
Mark
Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr.
(
- Contribution to journal › Article
- 2014
-
Mark
Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR])
(
- Contribution to journal › Article
-
Mark
Stent Thrombosis in New-Generation Drug-Eluting Stents in Patients With STEMI Undergoing Primary PCI: A Report From SCAAR.
(
- Contribution to journal › Article
-
Mark
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.
(
- Contribution to journal › Article
- 2011
-
Mark
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-A case-control study
(
- Contribution to journal › Article
- 2009
-
Mark
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
(
- Contribution to journal › Article
-
Mark
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article
- 2008
-
Mark
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article
-
Mark
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
(
- Contribution to journal › Article
-
Mark
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
(
- Contribution to journal › Article